Mo1847 - Reactive Dose Escalation of Infliximab in Patients with Crohn's Disease in Tailorix Leads to Improved Outcomes (original) (raw)
Philippe Van Hootegem
2018, Gastroenterology
visibility
…
description
2 pages
link
1 file
Pharmacogénétique de l’infliximab dans la maladie de Crohn
Vinciane Dideberg
Acta Endoscopica, 2007
View PDFchevron_right
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease
Philippe Van Hootegem
Clinical Gastroenterology and Hepatology, 2020
View PDFchevron_right
The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited
Lissy Ridder
Alimentary Pharmacology & Therapeutics, 2010
View PDFchevron_right
Retreatment and maintenance therapy with infliximab in fistulising Crohn's disease
ruth de francisco
Gastroenterology, 2003
View PDFchevron_right
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease
Nicolas Williet
Inflammatory Bowel Diseases, 2017
View PDFchevron_right
Induction Therapy With Biosimilar Infliximab in Children With Crohn Disease
Rizal Ardiansyah
Journal of Pediatric Gastroenterology & Nutrition, 2017
View PDFchevron_right
Serum protein profile of Crohn's disease treated with infliximab
Gerassimos Mantzaris
Journal of Crohn's and Colitis, 2013
View PDFchevron_right
Treatment Persistence for Infliximab Versus Adalimumab in Crohnʼs Disease
Pablo Olivera
Inflammatory Bowel Diseases, 2017
View PDFchevron_right
Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study
Csaba Dr Balázs
BMC Gastroenterology, 2009
View PDFchevron_right
Infliximab With Low-Dose Methotrexate for Prevention of Postsurgical Recurrence of Ileocolonic Crohn Disease
Giovanni Terrosu
Archives of Internal Medicine, 2007
View PDFchevron_right
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.
Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)
Ahmed Shelbaya
Advances in Therapy
View PDFchevron_right
Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease
guy lambrecht
Clinical Gastroenterology and Hepatology, 2020
View PDFchevron_right
Infliximab reverses growth hormone resistance associated with inflammatory bowel disease
Antonio Picardi
Alimentary Pharmacology and Therapeutics, 2005
View PDFchevron_right
Comparison of original and biosimilar infliximab (CTP-13) in biologic-na�ve patients with Crohn�s disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain
Keyla Villa
Revista Española de Enfermedades Digestivas, 2020
View PDFchevron_right
OP25 Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease
guy lambrecht
Journal of Crohn's and Colitis, 2019
View PDFchevron_right
Short-term treatment with infliximab in chronic refractory pouchitis and ileitis
G. Poggioli
Alimentary Pharmacology & Therapeutics, 2008
View PDFchevron_right
Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children
Eytan Wine
Inflammatory Bowel Diseases
View PDFchevron_right
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials
Peter Croucher
2002
View PDFchevron_right
Infliximab Therapy in 30 Patients With Refractory Pediatric Crohn Disease With and Without Fistulas in The Netherlands
Lissy Ridder
Journal of Pediatric Gastroenterology and Nutrition, 2004
View PDFchevron_right
Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
Bruce Salzberg MD, FACG
Inflammatory Bowel Diseases, 2018
View PDFchevron_right
Clinical Experience with Infliximab for Crohn’s Disease: The First 100 Patients in Edmonton, Alberta
Mang Ma
Canadian Journal of Gastroenterology, 2002
View PDFchevron_right
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients
William Sandborn
The American journal …, 2001
View PDFchevron_right
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response
Luis Abreu
Gastroenterología y hepatología
View PDFchevron_right
The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients
Jean-frédéric Colombel
Gastroenterology, 2004
View PDFchevron_right
Mo1865 - Ustekinumab Induces Clinical and Biological Remission in Biologic Refractory Crohn's Disease Patients: A Real World Belgian Cohort Study
Philippe Van Hootegem
Gastroenterology, 2018
View PDFchevron_right
Infliximab and the risk of latent viruses reactivation in active Crohnʼs disease
Massimiliano Bergallo
Inflammatory Bowel Diseases, 2007
View PDFchevron_right
A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency
Ali Keshavarzian
Gastroenterology & hepatology, 2007
View PDFchevron_right
Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease
Klaus Bendtzen
Alimentary Pharmacology & Therapeutics, 2011
View PDFchevron_right
Su1971 REAL-WORLD EFFECTIVENESS AND SAFETY OF USTEKINUMAB FOR THE TREATMENT OF CROHNS DISEASE: THE SCOTTISH USTEKINUMAB COHORT
jonathan macdonald
Gastroenterology, 2020
View PDFchevron_right
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians
William Sandborn
View PDFchevron_right
Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania
Letiţia Tugui, Cristina Toader, Carmen Preda
Romanian Journal of Gastroenterology, 2003
View PDFchevron_right
Favorable response to subcutaneous administration of infliximab in rats with experimental colitis
John Triantafillidis
World Journal of Gastroenterology, 2005
View PDFchevron_right
GastroenterologyMedicineClinical SciencesElsevierNeurosciencesPaediatrics and reproductive med...